Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Recruiting · NCT07200102 · Registry updated 2026-06-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-06-08 | NCT07200102 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Karyopharm Therapeutics Inc | 25 |
| Washington University School of Medicine | 475 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Washington University School of Medicine | St Louis | United States | 895 |